The NIHR, which is primarily based in the Bexley Wing at St James’s University Hospital, is now inviting people with head and neck cancer to join the trial.
Prof Chris Twelves, clinical director at the Leeds Teaching Hospitals NHS Trust NIHR Leeds CRF and Professor of Clinical Cancer Pharmacology and Oncology at the University of Leeds said: “This investigational cancer vaccine works by training the immune system to fight the cancer, which could be transformational for patients by slowing spread of the cancer and hopefully controlling their disease for longer.
“Thanks to the trust’s extensive team of clinical researchers and clinicians, we’re proud to now be a lead trial site for this innovative trial in people with advanced head and neck cancer.
“We are now working closely with our NHS partners across the region to ensure that suitable patients, like Richard, who are eligible for the trial have the opportunity to access these cutting-edge therapies right here in Leeds.”